| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $25,830 | 1 | 33 |
Sells | $1,088,801 | 2 | 67 |
| Johnson-Greene Treerita Essalima | Chief Financial Officer | 1 | $25,830 | 0 | $0 | $25,830 |
| Musunuri Shankar | Chief Executive Officer | 0 | $0 | 2 | $1.09M | $-1.09M |
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy …
Over the last 12 months, insiders at Ocugen, Inc. have bought $25,830 and sold $1.09M worth of Ocugen, Inc. stock.
On average, over the past 5 years, insiders at Ocugen, Inc. have bought $52,590 and sold $1.52M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Johnson-Greene Treerita Essalima (Chief Financial Officer) — $25,830.
The last purchase of 21,000 shares for transaction amount of $25,830 was made by Johnson-Greene Treerita Essalima (Chief Financial Officer) on 2026‑06‑15.
| 2026-10-09 | Sale | Musunuri Shankar | Chief Executive Officer | 525,991 0.1544% | $0.95 | $499,691 | -18.34% | |
| 2026-09-09 | Sale | Musunuri Shankar | Chief Executive Officer | 525,991 0.1631% | $1.12 | $589,110 | -7.15% | |
| 2026-06-15 | Johnson-Greene Treerita Essalima | Chief Financial Officer | 21,000 0.0063% | $1.23 | $25,830 | +2.87% | ||
| 2024-11-26 | Fernandes Prabhavathi | director | 10,000 0.0034% | $0.91 | $9,095 | +2.20% | ||
| 2024-11-22 | Castillo Kirsten | director | 25,000 0.0086% | $0.91 | $22,848 | +1.63% | ||
| 2023-06-14 | Zhang Junge | director | 200,278 0.0886% | $0.50 | $99,999 | +10.13% | ||
| 2023-02-16 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.046% | $1.08 | $108,000 | -49.04% | |
| 2023-01-17 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.045% | $1.28 | $128,000 | -56.90% | |
| 2022-12-16 | Sale | Musunuri Shankar | Chief Executive Officer | 95,809 0.0407% | $1.43 | $137,007 | -62.55% | |
| 2022-10-14 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.0484% | $1.66 | $166,000 | -49.62% | |
| 2022-10-06 | Sale | Kumar Ramesh | director | 4,500 0.0021% | $1.83 | $8,235 | -54.33% | |
| 2022-08-11 | Sale | Castillo Kirsten | 42,000 0.0211% | $2.91 | $122,220 | -58.58% | ||
| 2022-07-18 | Sale | Kumar Ramesh | 7,500 0.0036% | $2.57 | $19,275 | -49.19% | ||
| 2022-07-14 | Sale | Musunuri Shankar | Chief Executive Officer | 150,000 0.0716% | $2.72 | $408,000 | -52.09% | |
| 2022-05-13 | Sale | Musunuri Shankar | Chief Executive Officer | 125,000 0.0529% | $1.92 | $240,000 | -23.33% | |
| 2022-04-18 | Sale | Kumar Ramesh | 7,500 0.0038% | $2.83 | $21,225 | -33.85% | ||
| 2022-03-16 | Sale | Musunuri Shankar | Chief Executive Officer | 81,823 0.0367% | $2.65 | $216,831 | -31.01% | |
| 2022-02-14 | Sale | Musunuri Shankar | Chief Executive Officer | 90,000 0.045% | $3.74 | $336,600 | -39.01% | |
| 2022-01-18 | Sale | Kumar Ramesh | director | 7,500 0.0037% | $4.07 | $30,525 | -41.25% | |
| 2021-12-16 | Sale | Musunuri Shankar | Chief Executive Officer | 115,000 0.0613% | $5.22 | $600,300 | -50.70% |
| Musunuri Shankar | Chief Executive Officer | 1030771 0.304% | $768,130.55 | 2 | 18 | <0.0001% |
| Johnson-Greene Treerita Essalima | Chief Financial Officer | 521000 0.1536% | $388,249.20 | 1 | 0 | |
| Lewis Michael | 3610570 1.0647% | $2.69M | 2 | 1 | ||
| Wilmslow Estates Ltd | 10 percent owner | 3610570 1.0647% | $2.69M | 2 | 1 | |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2085848 0.6151% | $1.55M | 1 | 1 | |
| SPLIT ROCK PARTNERS II, LP | 10 percent owner | 1661495 0.49% | $1.24M | 2 | 1 | <0.0001% |
| Zhang Junge | director | 1077182 0.3176% | $802,716.03 | 8 | 2 | <0.0001% |
| RAKIN KEVIN | director | 245563 0.0724% | $182,993.55 | 2 | 1 | |
| Castillo Kirsten | director | 75000 0.0221% | $55,890.00 | 2 | 3 | +1.63% |
| Subramanian Sanjay | Chief Financial Officer | 35591 0.0105% | $26,522.41 | 2 | 7 | <0.0001% |
| GILL DAVID N | director | 14000 0.0041% | $10,432.80 | 4 | 0 | +2.86% |
| Fernandes Prabhavathi | director | 10000 0.0029% | $7,452.00 | 1 | 1 | +2.2% |
| Gridley Adam | President and CEO | 7000 0.0021% | $5,216.40 | 2 | 0 | <0.0001% |
| Lieber Jonathan I | Chief Financial Officer | 5000 0.0015% | $3,726.00 | 1 | 0 | <0.0001% |
$6,146,922 | 96 | -4.70% | $233.68M | |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 65 | +65.66% | 22M | +45.59% |
| Decreased Positions | 35 | -35.35% | 8M | -17.4% |
| New Positions | 33 | New | 6M | New |
| Sold Out Positions | 14 | Sold Out | 5M | Sold Out |
| Total Postitions | 129 | +30.3% | 61M | +28.19% |
| Vanguard Group Inc | $21,009.00 | 4.88% | 15.22M | +450,904 | +3.05% | 2025-09-30 |
| Millennium Management Llc | $5,744.00 | 1.33% | 4.16M | -896,777 | -17.73% | 2025-09-30 |
| Gmt Capital Corp | $5,732.00 | 1.33% | 4.15M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $5,595.00 | 1.3% | 4.05M | -2M | -27.48% | 2025-09-30 |
| Geode Capital Management, Llc | $5,075.00 | 1.18% | 3.68M | +189,391 | +5.43% | 2025-09-30 |
| Citadel Advisors Llc | $2,164.00 | 0.5% | 1.57M | +966,197 | +160.49% | 2025-09-30 |
| State Street Corp | $1,870.00 | 0.43% | 1.36M | +16,458 | +1.23% | 2025-09-30 |
| Rinkey Investments | $1,535.00 | 0.36% | 1.11M | -66,332 | -5.63% | 2025-09-30 |
| Gsa Capital Partners Llp | $1,437.00 | 0.33% | 1.04M | -686,963 | -39.74% | 2025-09-30 |
| Ubs Group Ag | $1,414.00 | 0.33% | 1.02M | +370,500 | +56.62% | 2025-09-30 |